REMS Modification Guidance Coming As FDA Rejects Petition For Shared REMS Rules
This article was originally published in The Pink Sheet Daily
Agency will wait until it has more experience with shared REMS before deciding whether to issue regulations or guidance on their implementation, but for now it hopes sponsors can work out problems on their own.
You may also be interested in...
Citing the use of Risk Evaluation and Mitigation Strategies to delay generic entry, Boston researchers urge Congress to revisit an “unintended consequence” created by the 2007 FDA Amendments Act.
One draft guidance may be released this year outlining how FDA evaluates the risk-management programs.
Additional draft guidances address implementation of the Drug Supply Chain Security Act, multiple endpoints in clinical trials, and public disclosure of FDA-sponsored studies.